

Q1 Figs. 3A and 3B show graphs illustrating the results of performing spectral analysis using cultured cells derived from mice breast cancer as a sample.

Figs. 4A and 4B show graphs illustrating the results of performing spectral analysis using cultured cells derived from mouse malignant melanoma as a sample.

Figs. 5A and 5B show graphs illustrating the results of performing spectral analysis using cultured cells derived from human stomach cancer as a sample.

Figs. 6A and 6B show graphs illustrating the results of performing spectral analysis using cultured cells derived from human glioblastoma as a sample.

Q2 Please replace the paragraph on page 7, lines 1-3, with the following paragraph:

-Figs. 7A and 7B show graphs illustrating the results of performing spectral analysis using cancer cells extracted from a breast cancer patient as a sample.

Please replace the paragraphs on page 7, lines 9-30, with the following paragraphs:

-Figs. 9A, 9B, and 9C show graphs illustrating changes in energy states caused by destruction of the cell membrane of cancer cells.

Figs. 10A, 10B, and 10C show graphs illustrating changes in energy states caused by heating cancer cells.

Q3 Figs. 11A and 11B show graphs illustrating the results of performing spectral analysis using normal rat brain (white matter) cells as a sample.

Figs. 12A and 12B show graphs illustrating the results of performing spectral analysis using normal rat liver cells as a sample.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

Q3 Figs. 13A and 13B show graphs illustrating the results of performing spectral analysis using normal mouse mammary gland cells as a sample.

Figs. 14A and 14B show graphs illustrating the results of performing spectral analysis using normal human bone marrow cells as a sample.

Please replace the paragraph on page 7, line 35 through page 8, line 1, with the following paragraph:

Q4 - Figs. 16A and 16B show graphs illustrating the results of performing spectral analysis using cisplatin as a sample.

Please replace the paragraphs on page 8, lines 3-12, with the following paragraphs:

- Figs. 17A and 17B show graphs illustrating the results of performing spectral analysis using carboplatin as a sample.

Q5 Figs. 18A and 18B show graphs illustrating the results of performing spectral analysis using doxorubicin hydrochloride (Adriacin) as a sample.

Figs. 19A and 19B show graphs illustrating the results of performing spectral analysis using nimustine hydrochloride (ACNU) as a sample.

Please replace the paragraph on page 8, line 34 through page 9, line 1, with the following paragraph:

Q6 - Figs. 25A and 25B show graphs illustrating the results of spectral analysis in the case of using Escherichia coli as a sample.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com